Indivior develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The Company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue and CNS disorders/schizophrenia. It markets and promotes Suboxone sublingual film, Suboxone sublingual tablet and Subutex sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex and Buprenex.

Type
Public
HQ
Slough, GB
Size (employees)
934 (est)
Indivior is headquartered in Slough, GB
Report incorrect company information

Indivior Office Locations

Indivior has offices in Ottawa, Richmond, Slough, Jersey and in 11 other locations
Slough, GB (HQ)
105 Bath Rd
Ottawa, CA
2 Gurdwara Rd
Beijing, CN
1 Dong San Huan Zhong Lu
Massy, FR
15 Rue Ampère
Mannheim, DE
3 Hermsheimer Str.
Milano, IT
7 Via Giovanni Spadolini
Show all (15)
Report incorrect company information

Indivior Financials and Metrics

Indivior Financials

Indivior's revenue was reported to be £819.39 m in FY, 2016 which is a 18.1% increase from the previous period.
GBP

Revenue (FY, 2016)

819.4 m

Revenue growth (FY, 2015 - FY, 2016), %

18.1%

Gross profit (FY, 2016)

736.5 m

Gross profit margin (FY, 2016), %

89.9%

Net income (FY, 2016)

27.1 m

EBITDA (FY, 2016)

122.4 m

EBIT (FY, 2016)

115.4 m

Market capitalization (31-Oct-2017)

2.7 b

Closing share price (31-Oct-2017)

3.5

Cash (31-Dec-2016)

535.9 m
Indivior's current market capitalization is £2.7 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

799.6 m762.9 m785.3 m819.4 m

Revenue growth, %

(5%)(9%)18%

Cost of goods sold

68.4 m65 m75.1 m82.9 m

Gross profit

731.2 m697.9 m710.2 m736.5 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

4.6 m226.5 m361.7 m535.9 m

Accounts Receivable

111.1 m110.8 m130.9 m158.8 m

Inventories

23.7 m28.1 m37.2 m31.8 m

Current Assets

149.9 m386.6 m558.4 m766.7 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

321.6 m275.7 m176.6 m27.1 m

Cash From Operating Activities

520.2 m301 m247.8 m315.2 m

Dividends Paid

157.2 m17.8 m53.4 m

Cash From Financing Activities

(530 m)(61.6 m)(111.5 m)(113.8 m)
GBPY, 2016

Financial Leverage

-4.1 x
Show all financial metrics

Indivior Operating Metrics

Indivior's Clinical Programs was reported to be 12 in FY, 2016.
FY, 2016

Clinical Programs

12

Phase I Trials Products

4

Phase II Trials Products

1

Phase III Trials Products

4
Show all operating metrics
Report incorrect company information

Indivior News and Updates

Thin Film Drug Manufacturing Market: Keen Players Coming up with Sophisticated Products to Beat Competition

Thin Film Drug Manufacturing Market report categorizes the global market by Product (Oral Thin Film & Transdermal Thin Film), Disease Indication (Schizophrenia, Migraine, Opioid Dependence, and Nausea and Vomiting), Distribution Channel & Geography Posted via Industry Today. Follow us on Twi…

Indivior pharma shares dive more than 20 per cent on US court ruling

UK pharmaceuticals company Indivior gave investors a bitter pill to swallow this morning, as it announced a US court found its rival had not infringed its patents. Shares in Indivior plummeted by more than 20 per cent on the open, as the company said that a Delaware court had found in favour of i…
Report incorrect company information